sarepta therapeutics layoffs

News

Sarepta Therapeutics to lay off 1-third of its workforce

Sarepta Therapeutics lays off one-third of workforce in drastic cost-cutting move

Sarepta Therapeutics announced it has laid off more than one-third of its workforce, a drastic cost-cutting move following the deaths of two teenagers administered its gene therapy for Duchenne muscular dystrophy.

The Wall Street Journal on MSN · 1d

Sarepta Therapeutics to Restructure, Lay Off 500 Workers

The gene-therapy company is restructuring, laying off 36% of its workforce and making changes to its executive team.

Seeking Alpha on MSN · 1d

Sarepta Therapeutics rises after restructuring, pipeline focus

Sarepta Therapeutics (NASDAQ:SRPT) saw its stock rise in after-hours trading following the announcement of a strategic review that will lead to a workforce reduction of approximately 500 employees, equating to a 36% decrease in staff.

Sarepta Says Another Patient Has Died

BioSpace · 2h

Sarepta Reports a Third Gene-Therapy Related Patient Death

The patient, who was being treated with an investigational gene therapy for limb-girdle muscular dystrophy, died of acute liver failure, the same complication responsible for the deaths of two boys taking Sarepta's Duchenne muscular dystrophy treatment Elevidys.

BioPharma Dive · 1d

Sarepta to lay off about 500 employees after Duchenne gene therapy setbacks

On a conference call, CEO Doug Ingram said the decision to cut 36% of the company's staff and halt several drug programs was essential to ensuring Sarepta's "long-term viability."

Bloomberg on MSN · 5h

Sarepta Says Another Patient Has Died After Gene Therapy

Sarepta Therapeutics Inc. said another patient has died from acute liver failure after receiving one of its gene therapies, putting additional pressure on the biotech company after the recent deaths of two teenage boys.

Sarepta Therapeutics Stock Plunges Over 30% In Friday Pre-Market: What's Going On

Shares of Sarepta Therapeutics (NASDAQ: SRPT) plunged 26.85% in Friday pre-market after a clinical trial participant died ...

1don MSN

Sarepta Stock Soars 30%. Why Layoffs and a ‘Black-Box’ Warning Are Good News.

Sarepta stock surged after the pharma company said it would lay off a third of its workforce and add a black-box warning to ...

STAT18h

Inside an FDA drug rejection, and layoffs at Sarepta

Just how many employees is Sarepta Therapeutics laying off? And why did the FDA reject Ultragenyx's rare disease drug over ...

Sarepta Therapeutics: What's Happening With SRPT Stock?

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

Fierce Biotech1d

Sarepta pivots to siRNA and lays off 500 staffers as Elevidys gets box warning

Sarepta Therapeutics is laying off 500 staffers, or 36% of its workforce, as part of a strategic restructuring aiming to save $400 million annually. | Sarepta Therapeutics has laid off 500 staffers, ...

BioSpace23h

Sarepta Up 18% After Business Overhaul as Analysts Cautiously Optimistic

Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...

Sarepta Therapeutics lays off one-third of workforce in drastic cost-cutting

The drastic cost-cutting move follows the deaths of two teenagers that forced the company to restrict usage of its gene therapy for Duchenne muscular dystrophy.

1don MSN

Sarepta Therapeutics Stock Soars on Beleaguered Drugmaker's Restructuring Plan

Shares of struggling drug developer Sarepta Therapeutics skyrocketed nearly 40% in extended trading Wednesday after the company unveiled a major restructuring plan.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results